Orakl Oncology raises $34M to test cancer drugs on "virtual patients" first

Orakl Oncology said on Nov. 12, 2026, it raised a €30 million ($34 million) Series A co-led by Norrsken VC and Singular to scale its AI "virtual cancer patient" platform.

Most cancer drugs that enter clinical trials never make it out, and every failure burns years and patients' time. Orakl's bet is that real tumors grown in a dish plus AI can call the result before the trial starts. The 90% accuracy figure is Orakl's own, so the proof will be whether pharma partners start killing or green-lighting drugs based on it.

Orakl Oncology said it raised a €30 million Series A, about $34 million. A Series A is the first large private round after a seed. A seed is the earlier, smaller check. Norrsken VC and Singular co-led. New investors are InfraVia Capital Partners, Serena, the Patient Autonome Fund managed by Bpifrance, Teampact Ventures, and Plug and Play. Bpifrance is France's public investment bank. Existing investors Verve Ventures, Speedinvest, and HCVC also joined. Angels, people investing their own money, include Dorothy Chou, Thomas Wolf, Stanislas Polu, Jacques Boitreaud, and Mostafa ElSayed. Total funding is now €45 million, about $50 million. The previous round was an €11 million seed led by Singular in December 2024. The announcement is dated Nov. 12, 2026. The amounts and the names are the company's, as EU-Startups, Tech Funding News, and Sifted reported them the same day.

Orakl was founded in 2023 as a spin-out of Gustave Roussy, the Paris cancer institute. A spin-out is a company that starts inside a lab or hospital and then stands on its own. The founders are chief executive Dr. Fanny Jaulin, chief technology officer Dr. Gustave Ronteix, and chief operating officer Dr. Diane-Laure Pagès. More than 40 people work there. Those lines are the company's.

The platform grows tumor organoids from real patients and pairs them with clinical and molecular data and with AI. An organoid is a small cluster of a patient's own tumor cells, grown in a dish so it behaves more like the tumor than a flat sheet of cells would. Orakl calls the result a virtual cancer patient. The aim is to predict how an oncology drug will perform in a clinical trial, which patients are likely to respond, and the mechanisms of sensitivity and resistance. A clinical trial is the human test a drug has to pass. Sensitivity means the drug works on that tumor. Resistance means it does not. Those lines are the company's.

Orakl says its predictive engine has shown 90% accuracy in predicting cancer clinical trial outcomes, including predictions that closely anticipated recent pancreatic cancer trial results. That 90% figure is the company's own claim. The reports do not attach an outside audit.

The company plans to expand beyond colorectal and pancreatic cancers into lung and gastric cancers, Tech Funding News reported. Colorectal cancer starts in the colon or rectum. Gastric cancer starts in the stomach. Startup coverage says Orakl has signed three contracts with pharmaceutical partners. That contract count is what the coverage attributes to the company. The reports do not name the partners.

The picture is the Orakl Oncology team, about 17 people, posing around a beige sofa in a bright office, with chief executive Fanny Jaulin seated at right in a black jacket. The credit is Orakl Oncology.

In plain terms, a Paris startup that came out of a cancer hospital raised about $34 million, co-led by Norrsken VC and Singular, to test cancer drugs on lab-grown patient tumors plus AI before a trial starts. The 90% accuracy figure is Orakl's. The round does not come with a valuation or a revenue number.